[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exacerbation-of-allergic-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exacerbation-of-allergic-asthma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100649023","phase-2-nebulized-ketamine-for-severe-asthma-attacks-in-children-100649023",false,"NCT07728851","Nebulized Ketamine for Severe Asthma Attacks in Children","Effectiveness and Safety of Nebulized Ketamine in Severe Pediatric Asthma: a Phase-2, Double-blind, Randomized, Placebo-controlled Pilot Trial","Inclusion Criteria:\n\n* Children aged 1 to 13 years.\n* Diagnosis of severe asthma exacerbation (PRAM score 8-12)\n* Prior treatment with standard first-line management (beta-2 agonist, corticosteroid, magnesium sulfate)\n\nExclusion Criteria:\n\n* Known allergy or adverse reaction to ketamine\n* Significant hemodynamic instability\n* Systemic hypertension \\>95th percentile for age\n* Cardiac arrhythmias\n* Congestive heart failure\n* Obstructive sleep apnea with AHI \\>5","ALL","1 Year","13 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a double-blinded, randomised, placebo-controlled trial enrolling 60 children aged 1 to 13 years with severe asthma exacerbation. All participants will receive standard therapy. Children not responding to standard therapy will be randomised to intervention arms. Randomization will occur in a 1:1 ratio using a computer-generated Excel sequence with permuted blocks of four, stratified by age (1-5 and 6-13 years). Patients will receive either nebulized ketamine (1 mg\u002Fkg every 6 hours for 24 hours) or 0.9% normal saline placebo. Randomization codes will be maintained by the hospital pharmacy, which will prepare identical numbered packs. During working hours, the pharmacist will dispense the allocated medication; at nights and weekends, pre-prepared packs will be stored securely in the PHDU\u002FPICU under the supervision of the nursing in-charge. Blinding will be maintained for patients, clinicians, and outcome assessors. PRAM scores will be recorded at baseline and at 20, 60, 90, and 120 minutes post-dose. The primary outcome is pediatric respiratory assessment measure (PRAM) score change. Secondary outcomes include need for NIV or intubation and HDU\u002FPICU length of stay.",[27,28],"Asthma Acute","Exacerbation of Allergic Asthma",[30,31],"Asthma","Ketamine","NOT_YET_RECRUITING","2026-07-23",{"date":35,"type":36},"2026-07-27","ACTUAL",{"date":38,"type":21},"2027-01-01",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Sultan Qaboos University","OTHER"]